ATXS
Price
$6.18
Change
-$0.35 (-5.36%)
Updated
Aug 29 closing price
Capitalization
348.77M
73 days until earnings call
ENTA
Price
$8.40
Change
-$0.29 (-3.34%)
Updated
Aug 29 closing price
Capitalization
179.57M
78 days until earnings call
Interact to see
Advertisement

ATXS vs ENTA

Header iconATXS vs ENTA Comparison
Open Charts ATXS vs ENTABanner chart's image
Astria Therapeutics
Price$6.18
Change-$0.35 (-5.36%)
Volume$235.51K
Capitalization348.77M
Enanta Pharmaceuticals
Price$8.40
Change-$0.29 (-3.34%)
Volume$75.9K
Capitalization179.57M
ATXS vs ENTA Comparison Chart in %
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. ENTA commentary
Aug 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and ENTA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 31, 2025
Stock price -- (ATXS: $6.18 vs. ENTA: $8.40)
Brand notoriety: ATXS and ENTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 85% vs. ENTA: 47%
Market capitalization -- ATXS: $348.77M vs. ENTA: $179.57M
ATXS [@Biotechnology] is valued at $348.77M. ENTA’s [@Biotechnology] market capitalization is $179.57M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileENTA’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • ENTA’s FA Score: 1 green, 4 red.
According to our system of comparison, ENTA is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while ENTA’s TA Score has 7 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 4 bearish.
  • ENTA’s TA Score: 7 bullish, 4 bearish.
According to our system of comparison, ENTA is a better buy in the short-term than ATXS.

Price Growth

ATXS (@Biotechnology) experienced а -8.98% price change this week, while ENTA (@Biotechnology) price change was -4.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.70%. For the same industry, the average monthly price growth was +20.57%, and the average quarterly price growth was +29.45%.

Reported Earning Dates

ATXS is expected to report earnings on Nov 12, 2025.

ENTA is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (-0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATXS($349M) has a higher market cap than ENTA($180M). ENTA YTD gains are higher at: 46.087 vs. ATXS (-30.872). ENTA has higher annual earnings (EBITDA): -82.41M vs. ATXS (-131.42M). ATXS has more cash in the bank: 259M vs. ENTA (204M). ATXS has less debt than ENTA: ATXS (4.77M) vs ENTA (58M). ENTA has higher revenues than ATXS: ENTA (64.8M) vs ATXS (0).
ATXSENTAATXS / ENTA
Capitalization349M180M194%
EBITDA-131.42M-82.41M159%
Gain YTD-30.87246.087-67%
P/E RatioN/AN/A-
Revenue064.8M-
Total Cash259M204M127%
Total Debt4.77M58M8%
FUNDAMENTALS RATINGS
ATXS vs ENTA: Fundamental Ratings
ATXS
ENTA
OUTLOOK RATING
1..100
7571
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
95
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
5446
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (55) in the Biotechnology industry is somewhat better than the same rating for ENTA (95). This means that ATXS’s stock grew somewhat faster than ENTA’s over the last 12 months.

ATXS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ENTA (100). This means that ATXS’s stock grew similarly to ENTA’s over the last 12 months.

ATXS's SMR Rating (97) in the Biotechnology industry is in the same range as ENTA (98). This means that ATXS’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's Price Growth Rating (46) in the Biotechnology industry is in the same range as ATXS (54). This means that ENTA’s stock grew similarly to ATXS’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for ATXS (100). This means that ENTA’s stock grew significantly faster than ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSENTA
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
69%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 9 days ago
80%
Bullish Trend 11 days ago
71%
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SBFFY27.810.68
+2.53%
SBM Offshore NV
BSFO27.20N/A
N/A
Bank of San Francisco
KSTBF0.05N/A
N/A
Kestrel Gold, Inc.
BKALF0.06N/A
N/A
Bank Aladin Syariah TBK PT
CAJPY29.31-0.37
-1.25%
Canon, Inc.

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with CRNX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
-5.36%
CRNX - ATXS
53%
Loosely correlated
+1.11%
XENE - ATXS
52%
Loosely correlated
+0.28%
NRIX - ATXS
51%
Loosely correlated
-0.74%
DNLI - ATXS
50%
Loosely correlated
-2.43%
COGT - ATXS
49%
Loosely correlated
N/A
More

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with ALEC. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then ALEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
-3.34%
ALEC - ENTA
40%
Loosely correlated
-1.67%
BEAM - ENTA
38%
Loosely correlated
-2.91%
ADCT - ENTA
36%
Loosely correlated
-5.54%
VRDN - ENTA
35%
Loosely correlated
-0.33%
AKRO - ENTA
35%
Loosely correlated
-0.45%
More